


 Cite this: *RSC Adv.*, 2024, **14**, 23559

 DOI: 10.1039/d4ra90079k
rsc.li/rsc-advances

Correction: Construction of antifungal dual-target (SE, CYP51) pharmacophore models and the discovery of novel antifungal inhibitors

 Yue Dong,^a Min Liu,^a Jian Wang,^b Zhuang Ding^a and Bin Sun^{*a}

Correction for 'Construction of antifungal dual-target (SE, CYP51) pharmacophore models and the discovery of novel antifungal inhibitors' by Yue Dong *et al.*, *RSC Adv.*, 2019, **9**, 26302–26314, <https://doi.org/10.1039/c9ra03713f>.

The authors regret that an incorrect version of Fig. 8 was included in the original article. The correct version of Fig. 8 is presented here.




Fig. 8 (A₁–₆) Polarizing microscopy results of *Candida albicans* treated with the positive control drugs (fluconazole and terbinafine) and the target compounds (5, 6 and 8) at the specific concentration of 8 mg mL^{−1}. (B₁–₄) TEM results for *Candida albicans* treated with the target compound (8) at the specific concentration of 8 mg mL^{−1}.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

^aInstitute of BioPharmaceutical Research, Liaocheng University, 1 Hunan Road, Liaocheng 252000, PR China

^bKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China

